Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

The cytidine analogues azacytidine and 5-aza-2'-deoxycytidine (decitabine) are commonly used to treat myelodysplastic syndromes, with or without a myeloproliferative component. It remains unclear whether the response to these hypomethylating agents results from a cytotoxic or an epigenetic effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Merlevede, Jane, Droin, Nathalie, Qin, Tingting, Meldi, Kristen, Yoshida, Kenichi, Morabito, Margot, Chautard, Emilie, Auboeuf, Didier, Fenaux, Pierre, Braun, Thorsten, Itzykson, Raphael, de Botton, Stéphane, Quesnel, Bruno, Commes, Thérèse, Jourdan, Eric, Vainchenker, William, Bernard, Olivier, Pata-Merci, Noemie, Solier, Stéphanie, Gayevskiy, Velimir, Dinger, Marcel E., Cowley, Mark J., Selimoglu-Buet, Dorothée, Meyer, Vincent, Artiguenave, François, Deleuze, Jean-François, Preudhomme, Claude, Stratton, Michael R., Alexandrov, Ludmil B., Padron, Eric, Ogawa, Seishi, Koscielny, Serge, Figueroa, Maria, Solary, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770084/
https://www.ncbi.nlm.nih.gov/pubmed/26908133
http://dx.doi.org/10.1038/ncomms10767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770084/
https://www.ncbi.nlm.nih.gov/pubmed/26908133
http://dx.doi.org/10.1038/ncomms10767

Ejemplares similares